Other, MHC class I–related ligand (nonclassical, MIC/ULBP superfamily), NKG2D ligand (ligand for KLRK1), GPI‑anchored cell‑surface glycoprotein (ULBP family characteristic)
01
Overview
UL16-binding protein 5 (ULBP5), also known as RAET1G, is a human MHC class I–related, stress‑induced cell‑surface ligand that binds and activates the NKG2D (KLRK1) receptor on natural killer cells and subsets of T cells. It belongs to the UL16‑binding protein family identified by their interaction with the HCMV glycoprotein UL16 and the broader group of human NKG2D ligands involved in immunosurveillance of infected and malignant cells. As with other ULBPs, its expression and availability at the cell surface can be regulated by viral immune evasion (intracellular retention by HCMV UL16) and by proteolytic processing mechanisms described for related ligands, which affect NKG2D‑mediated cytotoxic responses.
Other names
Retinoic acid early transcript 1G (RAET1G)NKG2D ligand (human) family member; part of the UL16‑binding proteins (ULBPs) familyUnique long 16 binding protein 5
02
Mechanism of action
Therapies targeting this axis generally act by:
- Enhancing NKG2D–ligand engagement to promote NK/T‑cell cytotoxicity
- Inhibiting proteolytic shedding of NKG2D ligands (e.g., metalloprotease inhibition shown for ULBP2/MICA) to increase surface ligand density
- Blocking viral immunoevasins (e.g., HCMV UL16) that retain selected NKG2D ligands intracellularly
03
Biological functions
Immune response activation via binding and activating NKG2D on NK cells and certain T cellsCo‑stimulation of cytokine production (e.g., synergizes with IL‑12 for IFN‑γ via NKG2D pathway; shown for ULBPs generally)Participation in stress‑induced immunosurveillance of infected or transformed cells as part of the NKG2D–ligand system
04
Disease associations
Cancer: NKG2D ligands are frequently expressed by tumors; ULBP family members can be shed and modulate tumor immune evasionInfection: Identified through interaction with HCMV UL16 and involved in antiviral immune recognition/evasion dynamics within the NKG2D systemPregnancy/placenta biology: ULBP1–5 are constitutively transcribed/expressed in early placenta; ULBP family implicated in trophoblast–uNK cell interactions
05
Safety considerations
On‑target immune activation: Broad enhancement of NKG2D signaling can risk off‑tumor NK/T‑cell activation and tissue damage where ligands are induced by stress or present physiologically (e.g., placenta), necessitating careful modulationLigand shedding dynamics: Metalloprotease‑mediated shedding alters efficacy and may cause systemic soluble ligands that interfere with NKG2D functions; inhibiting shedding might have complex immunological effectsViral immune evasion: Pathogen proteins (HCMV UL16) can alter ligand trafficking, complicating therapeutic strategies leveraging ULBP expression
06
Interacting drugs
None specifically approved that directly bind ULBP5 identified in the cited sources. Therapeutic agents in this axis typically target NKG2D or modulate NKG2D ligand expression/shedding; specific drug–ULBP5 interactions were not documented in these results.
07
Biomarkers
Soluble NKG2D ligands (e.g., sULBP2, sMICA) in serum as markers of tumor immune evasion and disease activityTissue expression of ULBP family members (including ULBP5 in early placenta) as contextual biomarkers in immunology of pregnancyCell‑surface ULBP expression as a biomarker for susceptibility to NKG2D‑mediated cytotoxicity in cancer/immunotherapy settings
Beyond the preview
Go deeper on UL16-binding protein 5 (ULBP5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on UL16-binding protein 5 (ULBP5).